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ABSTRACT
The PREDIMED (Prevención con Dieta Mediterránea) study was designed to assess the long-term effects of the Mediterranean diet (MeDiet) without
any energy restriction on incident cardiovascular disease (CVD) as a multicenter, randomized, primary prevention trial in individuals at high risk.
Participants were randomly assigned to 3 diet groups: 1) MeDiet supplemented with extra-virgin olive oil (EVOO); 2) MeDiet supplemented with nuts;
and 3) control diet (advice on a low-fat diet). After 4.8 y, 288 major CVD events occurred in 7447 participants; crude hazard ratios were 0.70 (95% CI:
0.53, 0.91) for the MeDiet + EVOO and 0.70 (95% CI: 0.53, 0.94) for the MeDiet + nuts compared with the control group. Respective hazard ratios for
incident diabetes (273 cases) among 3541 participants without diabetes were 0.60 (95% CI: 0.43, 0.85) and 0.82 (95% CI: 0.61, 1.10) compared with the
control group. After 1-y follow-up, participants in the MeDiet + nuts group showed a significant 13.7% reduction in prevalence of metabolic
syndrome compared with reductions of 6.7% and 2.0% in the MeDiet + EVOO and control groups, respectively. Analyses of intermediate markers of
cardiovascular risk demonstrated beneficial effects of the MeDiets on blood pressure, lipid profiles, lipoprotein particles, inflammation, oxidative stress,
and carotid atherosclerosis, as well as on the expression of proatherogenic genes involved in vascular events and thrombosis. Nutritional genomics
studies demonstrated interactions between a MeDiet and cyclooxygenase-2 (COX-2), interleukin-6 (IL-6), apolipoprotein A2 (APOA2), cholesteryl ester
transfer protein plasma (CETP), and transcription factor 7-like 2 (TCF7L2) gene polymorphisms. The PREDIMED study results demonstrate that a high-
unsaturated fat and antioxidant-rich dietary pattern such as the MeDiet is a useful tool in the prevention of CVD. Adv. Nutr. 5: 330S–336S, 2014.
Introduction
Cardiovascular diseases (CVDs) are the most important
threat for population health in the 21st century (1). Healthy
lifestyles and diets at younger and middle ages are key factors
for a life free of chronic diseases at later ages. It follows that
CVD prevention through diet and lifestyle is a public health
priority. Because diet appears to be particularly relevant in
CVD prevention, assessment of the “diet-heart hypothesis”
was actively investigated in nutritional epidemiology during
the past 50 y (2). In this context, analysis of food patterns,
rather than single nutrients and foods, is the ideal approach
to examine the effects of the overall diet with the synergistic
interaction of its food and nutrient components (3).
Many nutritional epidemiology studies assessing the diet-
heart hypothesis used intermediate biomarkers (reductions
in blood pressure, cholesterol, inﬂammatory molecules, or
other biomarkers) as a proxy for CVD risk. This approach
could be ﬂawed for several reasons. First, multiple pathways
lead from diet to CVD, thus negating a high value of changes
in single biomarkers. Second, the induction period can be
variable for the different pathways, limiting the possibility
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of assessing multiple biomarker combinations at any time
point. Third, unknown pathways might account for a substan-
tial proportion of CVD. Consequently, the best approach to
investigate the diet-heart hypothesis is to use hard clinical end-
points. A number of epidemiologic studies showed that overall
dietary patterns can improve health and prevent CVD to a
greater extent than isolated foods or nutrients (3,4). However,
most studies have been observational, and thus causal infer-
ence is problematic because of residual confounding and other
sources of bias. Thus, large randomized trials using food pat-
terns and assessing clinical endpoints are needed.
One food pattern reputed for its beneﬁcial health effects is
the Mediterranean diet (MeDiet)12; the traditional dietary
pattern followed by Mediterranean populations in the early
1960s) (2–8). It is characterized by the following: 1) abundant
use of olive oil; 2) high consumption of plant foods (fruits,
vegetables, legumes, cereals, nuts, and seeds); 3) frequent
but moderate intake of wine (especially red wine) with meals;
4) moderate consumption of fish, seafood, fermented dairy
products (yogurt and cheese), poultry, and eggs; and 5) low
consumption of red and processed meat and sweets.
The epidemiologic evidence on the CVD protection af-
forded by adherence to the MeDiet is strong. A systematic
review of 32 candidate dietary factors associated with coro-
nary heart disease ranked the MeDiet ﬁrst as the most likely
dietary model to provide causal protection (6), and there is
sound biologic plausibility for this effect (7). A meta-analysis
of observational studies (8) found strong evidence to support
a beneﬁcial effect of the MeDiet on CVD. In relation to inci-
dence of fatal and nonfatal CVD, the analysis of 8 cohorts to-
taling 534,064 individuals showed a 10% reduction associated
with a 2-point increase in a 9-point score of adherence to the
MeDiet. After this meta-analysis, the results of 7 additional
prospective studies were published up to October 2013 (9–
15). These new studies are shown in Table 1. We updated
this meta-analysis by using the same selection criteria and
methods of Sofi et al. (8). When the 7 new studies were added
to the previous meta-analysis and overlapping data were ex-
cluded, a new random-effect meta-analysis with 16 estimates
showed that each 2-point increment in a 0- to 9-point score
of adherence to the MeDiet was associated with a 10% relative
reduction in CVD (risk ratio: 0.90; 95% CI: 0.86, 0.94). After
removing studies that only assessed fatal CVD (10,14,16), the
inverse association became stronger (risk ratio: 0.87; 95% CI:
0.85, 0.90), with no evidence of heterogeneity (17).
The Lyon Diet Heart study, a landmark trial conducted in
survivors of a previous myocardial infarction (i.e., a secondary
prevention trial), tested a MeDiet enriched with a-linolenic
acid but not olive oil vs. a control diet and observed a strong
protection against recurrent coronary heart disease (18).
We designed a large-scale primary prevention feeding
trial, the PREDIMED (Prevención con Dieta Mediterránea)
study, with the hypothesis that the MeDiet would be supe-
rior to a low-fat diet for CVD protection (19). In this review,
we succinctly describe the design of the PREDIMED study
and present its main published results relating to CVD up
to 30 October 2013.
Current Status of Knowledge: The PREDIMED
Study
Design and implementation. The PREDIMED study was
designed to assess the long-term effects of the MeDiet on in-
cident CVD in men and women at high cardiovascular risk.
PREDIMED is a multicenter, randomized, nutritional inter-
vention trial for the primary prevention of CVD performed
in Spain from 2003 to 2011. The study was funded by the
ofﬁcial Spanish agency for scientiﬁc research, Instituto de
Salud Carlos III, and food industries donated the key foods
used in the study. Full details of the study protocol have been
described previously (19). Candidates were selected from
primary care facilities afﬁliated with 11 recruiting sites and
were at high risk of CVD but had no clinical disease at en-
rollment. Criteria for recruitment were age of 55–80 y and
the presence of diabetes or $3 risk factors (smoking, over-
weight or obesity, hypertension, dyslipidemia, and family
history of early-onset CVD )(Fig. 1). Participants were ran-
domly assigned into 1 of 3 interventions: 1) MeDiet sup-
plemented with extra-virgin olive oil (EVOO); 2) MeDiet
supplemented with nuts; and 3) control diet (advice on a
low-fat diet). Thus, the 2 MeDiet interventions were high
vegetable–fat dietary patterns.
The PREDIMED intervention was delivered by registered
dietitians. Throughout the study, participants attended quar-
terly individual visits and group sessions in which they were
instructed to follow the allocated diet. In the group sessions,
participants received written material with information on
key Mediterranean foods and seasonal shopping lists, menus,
and recipes for 1 wk. Those allocated into the corresponding
MeDiet groups were given free allocations of EVOO (1 L/wk,
including a minimum of 50 mL/d for participants and the rest
for family needs) or mixed nuts (30 g/d: 15 g of walnuts, 7.5 g
of almonds, and 7.5 g of hazelnuts plus extra allocations for
the family), whereas participants in the control diet group re-
ceived nonfood gifts. The diets were energy unrestricted, and
no increase in physical activity was promoted.
Dietitians used a speciﬁc tool to both assess actual adher-
ence to the MeDiet and enhance future adherence: a vali-
dated 14-point MeDiet score (20) (Table 2). Additional
information was collected yearly on lifestyle, habitual food
consumption with a validated FFQ covering 137 foods,
physical activity, health status, and medication changes. An-
thropometric and blood pressure measurements and an
electrocardiogram were taken yearly. Fasting blood and
spot urine samples were obtained, and serum, plasma, and
DNA samples were saved. Objective biomarkers of adher-
ence to the supplemental foods (urinary hydroxytirosol as
a marker of EVOO consumption and plasma a-linolenic
acid as a marker of walnut consumption) were determined
in random subsamples.
The primary endpoint was incident CVD (an aggregate of
nonfatal myocardial infarction, nonfatal stroke, and CVD
12 Abbreviations used: CHD, coronary heart disease; CVD, cardiovascular disease; EVOO,
extra-virgin olive oil; IL-6, interleukin-6; MeDiet, Mediterranean diet; MetS, metabolic
syndrome; PREDIMED, Prevencio´n con Dieta Mediterra´nea.
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death) (19,21). Secondary outcomes included total mortal-
ity, diabetes, metabolic syndrome (MetS), peripheral arterial
disease, atrial ﬁbrillation, neurodegenerative diseases, and
major cancers. An event adjudication committee, whose
members were blinded to group allocation, was responsible
for event ascertainment. The PREDIMED protocol was ap-
proved by the Institutional Review Boards of all participat-
ing centers. The main results are described below.
Effects on the main outcome: CVD. A total of 7447 candi-
dates were randomly assigned into the 3 PREDIMED inter-
vention groups (21). The groups were similar regarding
baseline clinical characteristics and drug treatment regimes.
The mean age of participants was 67 y, the mean BMI was
30 kg/m2, close to one-half had diabetes, two-thirds had dys-
lipidemia, and 4 of 5 had hypertension.
During follow-up, participants in the 2 MeDiet groups
improved the 14-point score of adherence to the MeDiet,
with statistically signiﬁcant differences vs. the control group
for 12 of the 14 points. Improved compliance with the MeD-
iet occurred early and was maintained throughout the dura-
tion of the trial. Compared with the control group, the main
dietary changes were large increases in consumption of
EVOO to 50 and 32 g/d and nuts to 0.9 and 6 servings
(30 g/serving) per week in the MeDiet + EVOO and MeDiet
+ nuts groups, respectively. Changes in objective biomarkers
indicated good compliance with the supplemental foods.
There were no between-group differences in physical ac-
tivity during the study. No diet-related adverse effects
occurred.
FIGURE 1 Design of the PREDIMED (Prevención con Dieta
Mediterránea) study. CVD, cardiovascular disease; EVOO, extra-
virgin olive oil; MeDiet, Mediterranean diet.
TABLE 1 Recent observational studies on adherence to the Mediterranean diet and cardiovascular disease1
Study Country Sample size Outcome Events Comment
Dilis et al., 2012 (12) Greece 23,929 CHD incidence and
death from CHD
636 CHD events and
240 CHD deaths
There was a stronger inverse as-
sociation for mortality than for
incidence.
Tognon et al., 2012
(13)
Sweden 77,151 CVD death 680 deaths The inverse association was only
signiﬁcant among women.
Effect of the dietary pattern
(only present among women)
was smaller than in studies
conducted in Mediterranean
countries.
Gardener et al., 2011
(14)
United States 2568 Stroke, myocardial
infarction, and
CVD death
518 events In a multiethnic population, a di-
etary pattern resembling the
Mediterranean diet was pro-
tective against the combined
outcome of ischemic stroke,
myocardial infarction, and vas-
cular death.
Misirli et al., 2012 (15) Greece 23,601 Stroke 395 incident cases and
196 stroke deaths
Inverse trends were stronger with
respect to ischemic rather than
hemorrhagic stroke.
Hoevenaar-Blom et al.,
2012 (16)
The Netherlands 40,011 Fatal and nonfatal
CVD events
4881 events, including
487 CVD deaths
There were signiﬁcant inverse lin-
ear associations for fatal CVD,
total CVD, myocardial infarc-
tion, and stroke.
Menotti et al., 2012
(17)
Italy 1139 CHD death 162 CHD deaths There was an inverse association
between an index of adequacy
to the Mediterranean diet and
total mortality in a male cohort.
Tognon et al., 2013
(18)
Denmark 1849 Fatal and nonfatal
CVD events
755 CVD events and
223 CVD deaths
Higher adherence to a
Mediterranean dietary score
was inversely associated with
CVD and myocardial infarction
but not with stroke.
1 Description of observational studies recently published but not included in the 2010 meta-analysis by Sofi et al. (8). CHD, coronary heart disease; CVD, cardiovascular disease.
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After 4.8 y, 288 major cardiovascular events occurred: 96
in the MeDiet + EVOO group (3.8%), 83 in the MeDiet +
nuts group (3.4%), and 109 in the control group (4.5%)
(21). The respective rates of the primary endpoint were
8.1, 8.0, and 11.2 per 1000 person-years. The unadjusted
hazard ratios were 0.70 (95% CI: 0.53, 0.91) for the MeDiet
+ EVOO and 0.70 (95% CI: 0.53, 0.94) for the MeDiet +
nuts (Fig. 2). Similar protection against CVD by the 2 MeDiets
vs. the control diet was shown after multivariable adjustment
for sex, age, adiposity variables, and baseline CVD risk factors.
No effect on all-cause mortality was apparent. Disease risk re-
ductions were similar across prespecified subgroups of sex,
age, and cardiovascular risk factors. Hence, the PREDIMED
study demonstrated for the first time with a randomized design
that a MeDiet supplemented with either EVOO or nuts is useful
in the primary prevention of CVD in individuals at high risk.
Regarding another CVD outcome, peripheral arterial dis-
ease, a strong relative risk reduction (>50%) was also apparent
in both MeDiet groups compared with the control group (22).
Effects on MetS and diabetes. As secondary endpoints of
the PREDIMED study, we also assessed the effects of the in-
terventions on diabetes incidence and MetS status. Based
mostly on epidemiologic evidence, MeDiet adherence has
been associated with a decreased risk of MetS (7) and diabetes
(23). There is also consistent evidence that intensive lifestyle
modiﬁcation promoting weight loss through energy-restricted
diets together with increased physical activity can reduce inci-
dent diabetes and is useful in managing MetS (7,23). However,
it was unknown whether dietary changes alone, without
weight loss or exercise, might also prevent these conditions.
Therefore, we hypothesized that the MeDiet interventions
in the PREDIMED study could protect against diabetes in
participants without diabetes and play a role in preventing
or managing MetS, a cluster of metabolic abnormalities that
predicts diabetes and cardiometabolic risk (24). MetS was de-
ﬁned by standard criteria as the presence of$3 of the follow-
ing factors: 1) abdominal obesity; 2) hypertriglyceridemia;
3) low HDL cholesterol; 4) elevated fasting blood glucose;
and 5) elevated blood pressure.
TABLE 2 Fourteen-point quantitative score of adherence to the Mediterranean diet
Point Foods and frequency of consumption Criteria for 1 point1
1 Do you use olive oil as main culinary fat? Yes
2 How much olive oil do you consume in a given day (including oil used for frying,
salads, out-of-house meals, etc.)?
$4 tablespoons
3 How many vegetable servings do you consume per day? (1 serving = 200 g;
consider side dishes as half servings)
$2 (at least 1 portion raw or as salad)
4 How many fruit units (including natural fruit juices) do you consume per day?
(1 unit = 150 g)
$3
5 How many servings of red meat, hamburger, or meat products (ham, sausage, etc.)
do you consume per day? (1 serving = 100–150 g)
,1
6 How many servings of butter, margarine, or cream do you consume per day?
(1 serving = 12 g)
,1
7 How many sweet/carbonated beverages do you drink per day? ,1
8 How much wine do you drink per week? $7 glasses
9 How many servings of legumes do you consume per week? (1 serving = 150 g) $3
10 How many servings of ﬁsh or shellﬁsh do you consume per week?
(1 serving = 100–150 g of fish, or 4–5 units or 200 g of shellfish)
$3
11 How many times per week do you consume commercial sweets or pastries
(not homemade), such as cakes, cookies, biscuits, or custard?
,3
12 How many servings of nuts (including peanuts) do you consume per week?
(1 serving = 30 g)
$3
13 Do you preferentially consume chicken, turkey, or rabbit meat instead of veal, pork,
hamburger, or sausage?
Yes
14 How many times per week do you consume vegetables, pasta, rice, or other dishes
seasoned with sofrito (sauce made with tomato and onion, leek, or
garlic, simmered with olive oil)?
$2
1 0 points if these criteria are not met.
FIGURE 2 Incidence of cardiovascular disease by intervention
group in the PREDIMED (Prevención con Dieta Mediterránea)
study. EVOO, extra-virgin olive oil; Med diet and MeDiet,
Mediterranean diet. Reproduced from reference 21 with
permission.
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Preliminary data from the PREDIMED study showed
that the MeDiets similarly decreased incident diabetes by
50% compared with the control diet after follow-up for
4.0 y (25). Of note, diabetes risk was reduced to a similar ex-
tent in participants of all treatment arms who reported
higher scores of adherence to the MeDiet. However, that re-
port was based on just 55 incident cases and dealt only with
participants from 1 recruiting center. Recently, we reported
the ﬁnal results on diabetes in the whole PREDIMED cohort
after follow-up for 4.1 y (26). Among 3541 participants
without diabetes at baseline, 273 cases of new-onset diabetes
occurred: 80 in the MeDiet + EVOO group, 92 in the MeDiet
+ nuts group, and 101 in the control group. After multivar-
iable adjustment, hazard ratios for diabetes were 0.60 (95%
CI: 0.43, 0.85) for MeDiet + EVOO and 0.82 (95% CI: 0.61,
1.10) for MeDiet + nuts compared with the control group.
These results extend those of previous observational studies
showing that lifestyle interventions, and speciﬁcally the
MeDiet, can reduce the incidence of diabetes in persons at
high risk (23), but here the beneﬁcial effect was mainly at-
tributable to diet alone, without other lifestyle changes.
We also evaluated the effect of intervention on MetS sta-
tus in the ﬁrst 1224 PREDIMED participants (27). At base-
line, 61.4% of participants met the criteria for MetS. After
1 y, those allocated to MeDiet + nuts showed a signiﬁcant
reduction in the prevalence of MetS by 13.7% compared
with reductions of 6.7% and 2.0% in the MeDiet + EVOO
and control groups, respectively. Between-group incident
MetS rates were similar, but reversion rates were signiﬁ-
cantly higher for the MeDiet + nuts.
Overall, these results show that a non-energy–restricted
MeDiet, a dietary pattern high in unsaturated fats and anti-
oxidants, could prevent diabetes and be useful in the man-
agement of MetS in high-risk individuals.
Mechanisms of protection: effects on intermediate
markers of cardiovascular risk. The PREDIMED study
also reported a beneﬁcial effect of the MeDiet on both clas-
sical and emergent risk factors. Results of the ﬁrst 772 par-
ticipants after intervention for 3 mo showed improved
blood pressure, insulin sensitivity, lipid proﬁle, and circulat-
ing inﬂammatory molecules with the 2 MeDiet interven-
tions vs. the control diet (28). A PREDIMED substudy
focusing on lipoprotein particles found that both MeDiets
increased large HDL particles, whereas the MeDiet + nuts
shifted LDL subfractions to a less atherogenic pattern (29).
In a recent report of the whole PREDIMED cohort after a
4-y follow-up, diastolic but not systolic blood pressure
values were lower after the 2 MeDiet interventions com-
pared with the control diet (30). Of note, no signiﬁcant
body weight changes occurred with any diet in the 3-mo
(28) and 1-y (27) assessments. Although traditional risk fac-
tors are critical for the development of atherosclerosis, the
basis for CVD, other interrelated processes are at play, in-
cluding endothelial dysfunction, inﬂammation, oxidative
stress, and genetic factors among others. Increased LDL cho-
lesterol is a potent atherogenic factor, but oxidatively
modiﬁed LDL particles are critical in the onset of atheroscle-
rosis and they were also reported to be decreased by the 2
MeDiets after 3 mo (31). Oxidation and inﬂammation are
pathogenic in many chronic conditions when sustained
over time. The reduction in inﬂammatory molecules dem-
onstrated after the 2 MeDiets in the 3-mo pilot study (28)
was conﬁrmed by the decrease of monocyte expression of
proinﬂammatory ligands after both MeDiets (32).
In a 1-y substudy, the 2 MeDiets reduced carotid intima-
media thickness among participants with a high intima-media
thickness at baseline (33). In a subsequent carotid ultrasound
study at 2 y, the MeDiet + nuts was associated with plaque re-
gression and the MeDiet + EVOO with delayed progression
compared with progression in the control group (34). Al-
though the underlying mechanisms of protection against
CVD by the MeDiet are not fully understood, the richness of
this dietary pattern in antioxidant and anti-inﬂammatory mol-
ecules is likely to be relevant (2,5). One mechanism of action of
nutrients relates to their capacity of modulating gene and pro-
tein expression and, subsequently, metabolite production. Pre-
vious nutrigenomic studies revealed that the MeDiet has a
protective effect on the expression of several proatherogenic
genes involved in vascular inﬂammation, foam cell formation,
and thrombosis (35,36). The MeDiet can also exert health ben-
eﬁts through changes in the overall transcriptomic response of
genes related to cardiovascular risk (37). CVD protection by
the MeDiet can be explained by a beneﬁcial impact on classical
and emergent cardiovascular risk factors, as well as nutrige-
nomic effects promoting antiatherogenic gene expression.
Nutritional genomics and the MeDiet within the
PREDIMED study. Nutritional genomic studies were in-
cluded in the design of the PREDIMED study to achieve a
better understanding of gene–diet interactions in determining
disease phenotypes (38,39). We sought to investigate whether
the effects of the MeDiet as a whole or its components might
differ depending on the genome. Gene expression studies fur-
ther expanded our knowledge of genes and pathways influ-
enced by the MeDiet. The PREDIMED study provides an
exceptional framework for undertaking nutrigenetic studies
because we can analyze the effect of different gene variants
on intermediate phenotypes (lipids, blood pressure, etc.)
and their interaction with diet, as well as effects of these inter-
actions on final disease phenotypes (CVD, cancer, etc.).
Cyclooxygenase-2 (COX-2) and interleukin-6 (IL-6) are 2
important genes related to inflammation (40). At baseline,
the COX-2 2765G > C polymorphism was associated with
lower serum IL-6 and intercellular adhesionmolecule-1 con-
centrations in carriers of the variant allele. The IL-6 2174G
> C polymorphism (CC vs. G-carriers) was associated with
higher serum intercellular adhesion molecule-1 concentra-
tions, but no gene2diet interactions were found after dietary
intervention. Thus, the MeDiet decreased inflammatory
markers regardless of genotype. Because an increasing num-
ber of genetic variants are being discovered (41), we de-
signed genetic analyses based on polymorphisms in new
genes uncovered by our analyses at the whole-transcriptome
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level (37). Another strategy was to replicate gene–diet inter-
actions described previously in other populations, such as
those involving the apolipoprotein A2 (APOA2) gene
(2265T > C) variant and saturated fat in determining
BMI in 3 American populations (42). We also observed
that the APOA2 saturated fat interaction was replicated in
PREDIMED participants (43). Continuing with the classic
polymorphisms, we analyzed the influence of the MeDiet
and fat intake on the effects of CETP polymorphisms
(24502C > T and the TaqIB) on lipids (44). In another
study, we focused on gene–diet interactions determining
obesity (45). A genetic score, including the melanocortin 4
receptor (MC4R) rs17782313 and fat mass and obesity
(FTO) rs9939609 variants, was strongly associated with
BMI; although there was no statistically significant interaction
with the MeDiet, greater adherence significantly reduced BMI
in genetically susceptible individuals. Additional assessment
of obesity-related variants focusing on the diabetes phenotype
(46) showed significant interactions between them and the
MeDiet in determining diabetes risk (greater adherence re-
duced risk in susceptible individuals).
Finally, we reported that intervention with MeDiet can
reduce genetic risk (47). We assessed the transcription factor
7-like 2 (TCF7L2) gene, strongly associated with diabetes
but controversially with plasma lipids and CVD, and found
that the MeDiets reduced the adverse effect of the TCF7L2
rs7903146 (C > T) polymorphism on cardiovascular risk
factors (fasting glucose and lipids) and stroke incidence.
Conclusions
To the best of the authors’ knowledge, PREDIMED demon-
strated for the first time in a randomized clinical trial that
the traditional MeDiet protects against CVD and confirmed
that it beneficially influences classical and emergent cardio-
vascular risk factors. Important teachings from this land-
mark study deserve to be discussed. First, the results
clearly show that a high-unsaturated fat dietary pattern is
better for cardiovascular health than a lower-fat diet. Sec-
ond, the PREDIMED MeDiets were successful in older per-
sons at high risk of CVD, most of whom were being treated
with antidiabetic, hypolipidemic, and/or antihypertensive
drugs; hence, it can be said that the MeDiet was effective
in controlling part of the residual risk observed after stan-
dard treatment of cardiovascular risk factors. Third, given
the age of PREDIMED participants, the results tell us that
it is never too late to change dietary habits to improve car-
diovascular health. Fourth, the supplemented foods given
to participants at no cost in the 2 MeDiet groups were in-
strumental in promoting good adherence to the overall die-
tary pattern. Thus, part of the success of the study might be
attributed to EVOO and nuts, unsaturated FA-rich and an-
tioxidant-rich foods that, despite their high fat content, did
not promote weight gain. Finally, nutritional genomic studies
show that adherence to the MeDiet blunts the development of
cardiometabolic phenotypes in genetically susceptible individ-
uals, a finding that concurs with previous evidence obtained
from alternate healthy dietary patterns. The PREDIMED study
was conducted in Spain, a Mediterranean population. Ex-
cept for the customary use of olive oil and regular intake
of wine with meals, the MeDiet does not differ from vegeta-
ble-based dietary patterns recommended for health in other
countries, so the findings are likely to be translatable to non-
Mediterranean populations, albeit with the quandary of
whether preferences, access, cost, and taste will permit using
olive oil and wine to a similar extent as in Mediterranean
Southern Europe.
Importantly, the 30% CVD risk reduction shown with the
MeDiet in the PREDIMED study is of similar magnitude to
that reported in the statin trials, although it is obtained at no
cost for the health system. To better deﬁne which diet is the
best for overall health, more randomized clinical trials of nutrit-
ion intervention with outcomes of clinical events are warranted.
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